Free Newsletter
Sanofi licenses technology for new TB vaccine
Sanofi Pasteur has struck a licensing deal with the Statens Serum Institut of Denmark covering the use of its technology for a new tuberculosis vaccine. The pact includes SSI's Intercell IC31 adjuvant and the use of certain fusion proteins. SSI TB vaccine candidates are recombinant protein sub-units, including one currently in a Phase I clinical trial. Results from a previous study showed the SSI TB vaccine technology provided a positive immune response. TB kills two million people a year.
"This agreement is a milestone for Sanofi Pasteur," said Wayne Pisano, president and CEO of Sanofi Pasteur, which is also working to develop a vaccine against another one of the biggest global infectious disease killers--malaria. "The current medical arsenal is inadequate for fighting tuberculosis."
- read the press release
Related Articles:
New compounds in works for tuberculosis. Report
Maxygen, Sanofi Pasteur ink $24.5M vaccine deal. Report
New approach to vaccine development. Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact




